Wednesday, July 8, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

Aflibercept

Approved · small molecule · Fibrovascular Pigment Epithelial Detachment

Aflibercept for Fibrovascular Pigment Epithelial Detachment is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

← All Regeneron UK Limited projects Approved small molecule terminated

Internal code EVER STUDY

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Approved
Modality
small_molecule
Indication
Fibrovascular Pigment Epithelial Detachment
Status
terminated
Trials
1